471. In-Depth Characterization of SARS-CoV-2 Variants Causing Breakthrough COVID-19 Among Hospitalized Immunocompromised (IC) Patients with or without Prior Exposure to Tixagevimab-Cilgavimab (T/C) Pre-Exposure Prophylaxis (PrEP)

BACKGROUND: PrEP with T/C can prevent COVID-19 hospitalization and death in IC patients (pts) up to 6 months after injection. However, in the USA, authorization of T/C PrEP was paused in Jan 2023 due to loss of in vitro activity of T/C against dominant circulating SARS-CoV-2 variants, although loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Haidar, Ghady, Jacobs, Jana L, Salese, Erin, Ludwig, Justin, Heaps, Amy, Parikh, Urvi, Sethi, Rahil, Caruso, Lori, Camacho, Haley, Chinakarn, Tina, Edick, Stacey, Fischer, Dawn, Kramer, Kailey Hughes, Lukanski, Amy, Marks, Kiersten, Saenz-Morales, Naomi, Sierra, Sara, Ferreira, Cátia, Glasser, Lisa, Heil, Kathleen, Talarico, Carla, Taylor, Sylvia, McCreary, Erin K, Mellors, John W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678141/
http://dx.doi.org/10.1093/ofid/ofad500.541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678141/
http://dx.doi.org/10.1093/ofid/ofad500.541

Ejemplares similares